🇺🇸 OXYTETRACYCLINE in United States

266 US adverse-event reports

Marketing authorisations

FDA

  • Status: approved

FDA

  • Application: NDA050287
  • Marketing authorisation holder: PFIZER
  • Local brand name: TERRAMYCIN
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 37 reports (13.91%)
  2. Drug Ineffective — 28 reports (10.53%)
  3. Fatigue — 27 reports (10.15%)
  4. Rash — 27 reports (10.15%)
  5. Confusional State — 26 reports (9.77%)
  6. Acute Kidney Injury — 25 reports (9.4%)
  7. Arthralgia — 25 reports (9.4%)
  8. Headache — 25 reports (9.4%)
  9. Diarrhoea — 23 reports (8.65%)
  10. Feeling Abnormal — 23 reports (8.65%)

Source database →

OXYTETRACYCLINE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is OXYTETRACYCLINE approved in United States?

Yes. FDA has authorised it; FDA has authorised it.

Who is the marketing authorisation holder for OXYTETRACYCLINE in United States?

Marketing authorisation holder not available in our data.